European Commission approves TECVAYLI (teclistamab) monotherapy for relapsed/refractory multiple myeloma October 27, 2026
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Ph 2/3 Clinical Trial Collaboration to Evaluate Ivonescimab in 1L BTC October 27, 2026
University of California, Davis activated as a Clinical Trial Site for Ongoing Ph 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies October 27, 2026
Global Ph 2 Study of Ivonescimab in 1L Clear Cell RCC, Including Combination with Cadonilimab, initiated October 27, 2026
Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in PFS and OS in Patients with Platinum-Resistant Ovarian Cancer October 27, 2026
CHMP recommends approval of TALVEY® (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma October 27, 2026
New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) accepted for review by the China NMPA October 27, 2026
FDA grants traditional approval for Keytruda or Keytruda Qlex for unresectable or metastatic TMB-H solid tumors with updated indication October 27, 2026
European Commission Approves KEYTRUDA® + Padcev® as Perioperative Treatment for Adults With Resectable MIBC October 27, 2026
